Jump to Navigation
Quantitative
Research
Quantitative Models
Methodology Graphic
EQR White Paper
Investment
Products
Baker's Dozen Model Portfolio
UITs
ETFs
Investor
Tools
Scorecards
Earnings Busters
Sector Detector
Advisors &
Individual Investors
Go to Investors Site
About Us
Our Company
Our People
ADV2A
Contact Us
Search form
Search
You are here:
You are here
Home
Aurinia targets $305M–$315M LUPKYNIS sales for 2026 while advancing aritinercept clinical development
Seeking Alpha
-
Thu, 02/26/2026 - 14:28
ITT Inc. (ITT) Presents at 36th Annual Pump, Valve, and Water Systems Symposium - Slideshow
Seeking Alpha
-
Thu, 02/26/2026 - 14:28
Credo Q3 Preview: Asymmetry Is The Art Of Alpha
Seeking Alpha
-
Thu, 02/26/2026 - 14:23
Wendel reports FY results
Seeking Alpha
-
Thu, 02/26/2026 - 14:21
Adtran outlines $275M-$295M Q1 2026 revenue target as fiber and optical momentum continues
Seeking Alpha
-
Thu, 02/26/2026 - 14:18
GoodRx expects Pharma Direct revenue growth of at least 30% in 2026 amid shift to pharma manufacturer solutions
Seeking Alpha
-
Thu, 02/26/2026 - 14:18
Delcath targets at least $100M revenue in 2026 while expanding to 40 treatment centers
Seeking Alpha
-
Thu, 02/26/2026 - 14:18
U.S. Stocks Sell Off On Nvidia’s Good News, As Traders Wait For Results Of Key UK Election
TalkMarkets
-
Thu, 02/26/2026 - 14:11
It’s never a good sign when markets sell off on good news, but that is exactly what happened on Thursday.
Nvidia Keeps Raising The Bar
Seeking Alpha
-
Thu, 02/26/2026 - 14:11
Novavax outlines $230M–$270M 2026 revenue target with new Pfizer partnership and cost reduction strategy
Seeking Alpha
-
Thu, 02/26/2026 - 14:09
NCR Voyix outlines $2.21B–$2.325B revenue outlook for 2026 as platform scaling accelerates
Seeking Alpha
-
Thu, 02/26/2026 - 14:09
Millrose projects $2B invested capital rise outside Lennar in 2026 as platform diversification advances
Seeking Alpha
-
Thu, 02/26/2026 - 14:09
Global Net Lease outlines $0.80–$0.84 AFFO per share guidance for 2026 while advancing portfolio transformation
Seeking Alpha
-
Thu, 02/26/2026 - 14:09
Chemed forecasts 5.5%–6.5% VITAS revenue growth and signals 55% of 2026 earnings to be back-half weighted amid transition initiatives
Seeking Alpha
-
Thu, 02/26/2026 - 14:09
Rhythm anticipates $385M–$415M in 2026 non-GAAP operating expenses as HO launch preparations accelerate
Seeking Alpha
-
Thu, 02/26/2026 - 14:09
BioCryst outlines $625M–$645M 2026 ORLADEYO revenue target as HAE pipeline advances
Seeking Alpha
-
Thu, 02/26/2026 - 14:09
Universal Health Services outlines 2026 revenue target of up to $18.8B while accelerating AI and outpatient expansion
Seeking Alpha
-
Thu, 02/26/2026 - 14:09
Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment
Seeking Alpha
-
Thu, 02/26/2026 - 14:09
NexPoint outlines $0.40–$0.45 Q1 2026 EAD guidance while advancing Life Science and BTR strategies
Seeking Alpha
-
Thu, 02/26/2026 - 14:09
Emcor outlines $17.75B-$18.5B 2026 revenue target as RPOs hit $13.25B, driven by data center demand
Seeking Alpha
-
Thu, 02/26/2026 - 14:09
Pages
« first
‹ previous
…
1854
1855
1856
1857
1858
1859
1860
1861
1862
…
next ›
last »